文献速递心境障碍

双相II障碍:最新综述

Bipolar II disorder: a state-of-the-art review.
PubMed 文献 · World Psychiatry · 2025-01-01

本文综述双相II障碍的诊断标准、临床表现、共病、流行病学、危险因素与治疗策略。患者抑郁发作远多于轻躁狂发作,常被误诊为重性抑郁障碍并单用抗抑郁药。证据提示其功能与认知损害显著、自杀风险至少与双相I障碍相当。

要点

  • 双相II障碍抑郁发作与轻躁狂发作比例达39:1,易误诊为重性抑郁障碍。
  • 自杀完成率至少与双相I障碍相当,需重视风险评估。
  • 治疗以心境稳定剂与非典型抗精神病药为主,辅以心理教育、认知行为或人际社会节律治疗及生活方式干预。

核心结论

  • 双相II障碍是DSM-5与ICD-11识别的独立亚型,功能与认知损害显著且自杀风险至少与双相I障碍相当。
  • 现有治疗指南多从双相I障碍与抑郁研究外推,可能未完全覆盖双相II障碍的独特 aspects。

研究设计与样本

  • 本文为叙述性综述,汇总双相II障碍现有研究与当前争论,涵盖诊断标准、临床表现、共病、流行病学、危险因素与治疗策略。

主要发现

  • 双相II障碍患者抑郁发作与轻躁狂发作之比为39:1,常被误诊为重性抑郁障碍并接受抗抑郁药单药治疗,可能恶化预后。
  • 症状与边缘型人格障碍重叠使识别更复杂,焦虑与物质使用障碍等精神共病常见。
  • 躯体共病患病率高,其中心血管疾病共病风险尤其高。
  • 炎症、昼夜节律失调与线粒体功能障碍正被研究为潜在病理生理机制。

关键数值与推荐

  • DSM-5与ICD-11均将双相II障碍定义为至少一次抑郁发作和至少一次轻躁狂发作,且无躁狂史。
  • 有实质证据支持心境稳定剂与非典型抗精神病药的药物治疗价值,并辅以心理教育、认知行为或人际社会节律治疗及生活方式干预。

临床怎么用

  • 对反复抑郁发作者应筛查轻躁狂史,避免将双相II障碍误诊为重性抑郁障碍并单用抗抑郁药。
  • 评估需关注边缘型人格障碍重叠、焦虑与物质使用共病及心血管疾病风险。
  • 治疗以心境稳定剂与非典型抗精神病药为基础,联合心理教育、认知行为或人际社会节律治疗及生活方式干预。

局限性

  • 原文指出双相II障碍相关文献仍相对稀疏,治疗指南多从双相I障碍与抑郁研究外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bipolar II disorder (BD-II) is currently identified by both the DSM-5 and ICD-11 as a distinct subtype of bipolar disorder, defined by at least one depressive episode and at least one hypomanic episode, with no history of mania. Despite its prevalence and impact, the literature on BD-II remains relatively sparse. This paper provides a comprehensive overview of the available research and current debate on the disorder, including its diagnostic criteria, clinical presentations, comorbidities, epidemiology, risk factors, and treatment strategies. Patients with BD-II often present with recurrent depressive episodes, which outnumber hypomanic episodes by a ratio of 39:1. The condition is therefore often misdiagnosed as major depressive disorder and treated with antidepressant monotherapy, which may worsen its prognosis. The recognition of BD-II is further complicated by the overlap of its symptoms with other disorders, in particular borderline personality disorder. Although BD-II is often perceived as a less severe form of bipolar disorder, evidence suggests significant functional and cognitive impairment, accompanied by an elevated risk of suicidal behavior, including a rate of completed suicide at least equivalent to that observed in bipolar I disorder (BD-I). Psychiatric comorbidities, in particular anxiety and substance use disorders, are common. The disorder is associated with a high prevalence of numerous physical comorbidities, with a particularly high risk of comorbid cardiovascular diseases. Various genetic and environmental risk factors have been identified. Inflammation, circadian rhythm dysregulation and mitochondrial dysfunction are being studied as potential pathophysiological mechanisms. Current treatment guidelines, often extrapolated from BD-I and depression research, may not fully address the unique aspects of BD-II. Nevertheless, substantial evidence supports the value of some pharmacological treatments - primarily mood stabilizers and atypical antipsychotics - augmented by psychoeducation, cognitive behavioral or interpersonal and social rhythm therapy, and lifestyle interventions. Further research on BD-II should be a priority, in order to refine diagnostic criteria, identify potentially modifiable risk factors, and develop targeted interventions.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Berk M, Corrales A, Trisno R, et al. Bipolar II disorder: a state-of-the-art review. World Psychiatry. 2025. PMID: 40371769. doi:10.1002/wps.21300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。